Drug Trial Radar · NCT05928780
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)
Last checked: Nov 19, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
125
Planned (sponsor's estimate)
Start
Jul 1, 2023
Primary completion
Mar 1, 2024
Study completion Sep 1, 2025
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To explore the efficacy and safety of TROP2 in the treatment of ABC
Conditions
- TNBC - Triple-Negative Breast Cancer
Interventions
A1:SG with SHR3680Drug
SG 10mg/kg d1, 8;SHR3680 240mg qd,3 weeks is a cycle
A2:SGDrug
SG 10mg/kg d1, 8
B1:SG with SHR1210Drug
SG 10mg/kg, d1, 8;SHR1210 200mg,d1,q3w;
B2:SGDrug
SG 10mg/kg, d1, 8
C1:SG with SHR3162Drug
SG 10mg/kg d1, 8;SHR3162,150mg,QD ,3 weeks is a cycle
C2:SGDrug
SG 10mg/kg d1, 8
D1:SG with VEGFRIDrug
SG 10mg/kg,d1, 8;BP102 15mg/kg,d1,3 weeks is a cycle
D2:SGDrug
SG 10mg/kg d1, 8
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: max 6 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.